GLP-1 Weight Loss Drugs UK: NHS Access, Costs & Waiting Lists in 2026

Overview

GLP-1 (glucagon-like peptide-1) receptor agonists are the most significant advance in obesity pharmacotherapy in a generation. In the UK, the arrival of Wegovy (semaglutide 2.4 mg) and Mounjaro (tirzepatide) has coincided with a national obesity crisis in which over 28% of adults in England are classified as obese (NHS Digital, 2023). The NHS has implemented access through specialist weight management services, but demand has dramatically outpaced supply, creating waiting lists of 12–24 months in many integrated care board (ICB) areas. Meanwhile, private clinics have expanded rapidly to meet demand, and high street pharmacy chains including Boots have entered the market. This guide explains the complete UK GLP-1 landscape in 2026 — every approved drug, NHS eligibility rules, costs, availability, the pipeline, and how to navigate the system as a UK patient.

Approved GLP-1 Drugs in the UK: Current Status

The MHRA has approved several GLP-1 receptor agonists, each with specific licensed indications. Understanding what is approved for what purpose is essential for navigating NHS and private access:

• Ozempic (semaglutide 0.5 mg, 1 mg, 2 mg injection): MHRA-approved for type 2 diabetes management. Not licensed in the UK for weight loss. Widely known for off-label weight loss use following media coverage. Available on NHS prescription for diabetes via primary care. Monthly cost privately: £100–£180 depending on dose.
• Wegovy (semaglutide 2.4 mg injection): MHRA-approved for chronic weight management in adults with BMI ≥30, or ≥27 with at least one weight-related comorbidity. NHS implementation gated behind NICE TA875 and Tier 3 weight management service referral. Supply shortages affected availability in 2023–2024; stock stabilised in late 2024. Private cost: £200–£350/month at maintenance dose.
• Rybelsus (oral semaglutide): MHRA-approved for type 2 diabetes. Not licensed for weight loss. Available via NHS diabetes prescribing.
• Mounjaro (tirzepatide 2.5 mg–15 mg injection): MHRA-approved for type 2 diabetes (since 2023) and weight management (since late 2024 following NICE TA1026). Dual GIP/GLP-1 agonist — often described as more effective than semaglutide for weight loss. NHS weight management rollout is ongoing through ICB specialised commissioning. Private cost: £150–£250/month depending on dose.
• Victoza/Saxenda (liraglutide): Victoza is MHRA-approved for type 2 diabetes; Saxenda (3 mg) for obesity. Older GLP-1 agent, daily injection. NHS prescribing for weight management restricted; largely supplanted by semaglutide and tirzepatide. Still available privately.
• Trulicity (dulaglutide): MHRA-approved for type 2 diabetes only. Not licensed for weight management. Weekly injection.
• Byetta/Bydureon (exenatide): Older GLP-1 agent, approved for diabetes. Not in routine NHS use for weight management.

NHS Eligibility: Tier 3 Services, BMI Thresholds, and Comorbidities

Access to GLP-1 drugs for weight management on the NHS is not available through simple GP prescription. The NHS has implemented a specialist pathway that patients must navigate. For Wegovy (semaglutide), NICE TA875 requires: referral to a Tier 3 specialist weight management service (or, in some ICBs, a primary care pathway embedded within the Tier 3 framework); a BMI of ≥35 kg/m² (or ≥32.5 for patients of South Asian, Chinese, Black African, African-Caribbean, or other ethnicities where risk is elevated at lower BMI); and the presence of at least one weight-related comorbidity — most commonly type 2 diabetes or pre-diabetes, hypertension, obstructive sleep apnoea, dyslipidaemia, cardiovascular disease, or fatty liver disease. The medication must form part of a multi-component programme including dietary advice, behavioural support, and physical activity guidance. Treatment under NICE TA875 is funded for a maximum of two years, after which continued prescribing requires individual clinical review and commissioner approval. For Mounjaro (tirzepatide), NICE TA1026 sets broadly similar criteria (BMI ≥35 or ≥32.5 for higher-risk groups with at least one comorbidity) but is being implemented through a separate commissioning route during the NHS England managed rollout. As of early 2026, not all ICBs have activated Mounjaro prescribing through their Tier 3 services, creating postcode lottery access. Patients with type 2 diabetes can access GLP-1 agonists including Ozempic through standard primary care HbA1c and diabetes management pathways without the Tier 3 requirement.

NHS Waiting Lists: The 12–24 Month Reality

One of the most significant barriers to NHS GLP-1 access in 2026 is waiting time. Following the introduction of NICE TA875 in 2023, Tier 3 weight management services across England were rapidly overwhelmed. Many ICBs report referral-to-appointment waiting times of 12–18 months, and in London, the South East, and parts of the North West, waits of 18–24 months or longer have been documented by patient advocacy groups and NHS waiting time transparency reports. The Tier 3 pathway itself then requires a multi-appointment assessment process — typically three to six months of dietary, psychological, and medical assessment before any pharmacotherapy is initiated. This means the realistic time from GP referral to first Wegovy injection via the NHS can exceed two years in some areas. Contributing factors include: historically under-resourced Tier 3 services; a rapid increase in GP referrals following media coverage of semaglutide's efficacy; limited numbers of trained obesity medicine clinicians; and NHS England's deliberate managed-rollout approach to avoid uncontrolled expenditure growth. Some ICBs have piloted primary care-embedded GLP-1 prescribing models that aim to reduce the specialist bottleneck, but these are not uniformly available. Patients who cannot wait — and can afford private access — typically gain same-week to same-month access through private online or in-person clinics.

Cost: NHS vs Private in 2026

The financial picture for UK GLP-1 access varies enormously by route. NHS access, for eligible patients who successfully complete the Tier 3 pathway, is free at the point of use — patients pay only the standard NHS prescription charge (£9.90 per item as of 2025/26) or are exempt from charges under standard NHS exemption rules. Private access removes the eligibility and waiting time barriers but introduces significant cost. The following represents typical 2026 private market pricing:

• Wegovy (semaglutide 2.4 mg): £200–£350/month at maintenance dose; lower at introductory doses (0.25–0.5 mg/week) — some providers price these at £100–£160/month
• Mounjaro (tirzepatide): £150–£250/month at mid-range doses (5–10 mg/week); up to £280–£300/month at 15 mg/week maintenance
• Ozempic (semaglutide, diabetes-licensed): £100–£180/month when prescribed privately for weight management off-label at lower doses
• Saxenda (liraglutide): £100–£180/month — less commonly used given efficacy advantage of newer agents
• Consultation and assessment fees: £50–£150 initial consultation; ongoing monthly monitoring fees of £15–£50 vary by provider
• NHS prescription charge: £9.90/item (2025/26); many weight loss patients are exempt if they have type 2 diabetes
• Total annual cost privately: approximately £1,800–£4,200 depending on drug, dose, and provider

NICE Guidance Breakdown: TA875 and TA1026

NICE Technology Appraisals are the primary mechanism by which new NHS treatments are commissioned in England. Two appraisals govern GLP-1 access for weight management. NICE TA875 (semaglutide, published March 2023) recommends Wegovy as an option for managing overweight and obesity only if used alongside a reduced-calorie diet and increased physical activity within a specialist weight management service; the patient has a BMI ≥35 kg/m² (or ≥32.5 for higher-risk groups); has at least one weight-related comorbidity; and the treatment is stopped after 2 years unless re-authorised. The appraisal was notable for being among the most cost-effective NICE approvals in recent years, with semaglutide meeting the standard £20,000–£30,000 per QALY threshold even at list price — partly due to the substantial long-term health cost savings from sustained weight loss in high-BMI patients with comorbidities. NICE TA1026 (tirzepatide, published December 2024) similarly recommends Mounjaro for adults with BMI ≥35 (or ≥32.5 for higher-risk ethnicities) with at least one weight-related comorbidity. The appraisal noted that head-to-head trial data (the SURMOUNT-5 trial) showed tirzepatide producing approximately 20% greater weight loss than semaglutide at equivalent treatment durations, strengthening its cost-effectiveness case. Both appraisals apply only to England; Scotland, Wales, and Northern Ireland have their own medicines appraisal bodies (SMC, AWMSG, and the Northern Ireland HSC respectively) and may have different availability timelines.

Pharmacy Availability: Boots, LloydsPharmacy and High-Street Access

The entry of major UK pharmacy chains into the GLP-1 market has significantly broadened access pathways for private patients. Boots launched its online weight management service in 2023, offering access to Wegovy and later Mounjaro through an online consultation with a Boots clinician followed by home delivery of the prescription. Boots' service is fully CQC-regulated, uses licensed products, and integrates with Boots' established pharmacy dispensing infrastructure. The service charges a consultation fee plus monthly product cost and has become one of the most-used private GLP-1 access points in the UK due to brand trust and accessibility. LloydsPharmacy, though it closed its retail estate, retained its clinical homecare and online pharmacy services. LloydsPharmacy Clinical Homecare has continued to play a role in NHS Tier 3 medication delivery, particularly for injectable biologics including Wegovy. High-street pharmacies including independent pharmacists and smaller chains can dispense NHS or private prescriptions for Wegovy and Mounjaro where stock is available. Post-shortage supply of Wegovy stabilised significantly in late 2024 following Novo Nordisk's production scale-up, and Mounjaro availability has been generally strong since its weight management licence. Patients with private prescriptions can now typically obtain these medications within a few days, a stark contrast to the six-to-eight-week waits experienced during the 2023 shortage.

What's Coming: Survodutide, Retatrutide and the UK Pipeline

Beyond semaglutide and tirzepatide, a wave of next-generation GLP-1 and multi-receptor agonist drugs is advancing through clinical development, with several expected to seek MHRA authorisation in 2026–2028. Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim. Phase 2 data presented in 2023–2024 showed approximately 19% body weight reduction over 46 weeks in adults with obesity — competitive with tirzepatide. Phase 3 trials are underway; MHRA application is anticipated in 2026–2027 if results are positive. Retatrutide (LY3437943) from Eli Lilly is a triple agonist targeting GLP-1, GIP, and glucagon receptors, which showed up to 24% body weight reduction in phase 2 — the highest ever recorded for a once-weekly injectable weight loss drug. The TRIUMPH Phase 3 programme is ongoing; UK MHRA submission may follow US FDA filing in 2026–2027. Orforglipron is an oral non-peptide GLP-1 receptor agonist from Eli Lilly in Phase 3 trials. As a once-daily tablet rather than an injection, it could dramatically expand the patient population willing to engage with GLP-1 therapy. CagriSema (cagrilintide + semaglutide co-formulation from Novo Nordisk) combines an amylin analogue with semaglutide; Phase 3 REDEFINE results showed approximately 22% weight loss. MHRA filing anticipated in late 2026. The UK pipeline is therefore exceptionally active. NICE will need to rapidly appraise multiple new agents over the next 24–36 months, and NHS commissioning frameworks will need to evolve to accommodate the expanding treatment options.

Navigating the NHS Pathway: Practical Tips for UK Patients

For UK patients seeking NHS GLP-1 access, the following practical steps can meaningfully improve their chances and reduce waiting time:

• Request a formal NHS BMI assessment and comorbidity review from your GP — documented clinical evidence of eligibility is essential for Tier 3 referral
• Ask your GP explicitly to refer you to your ICB's Tier 3 weight management service by name; generic referrals may be lost or delayed in administrative routing
• Check your ICB's website for their specific Tier 3 service provider (some ICBs use Tier 3 services embedded in GP-based primary care networks, which have shorter waits than hospital-based services)
• If you have type 2 diabetes, ask your GP or diabetes nurse about Ozempic or Mounjaro via the standard HbA1c pathway — this bypasses the Tier 3 weight management queue entirely
• Consider whether you qualify for an NHS Individual Funding Request (IFR) if your circumstances are exceptional — for instance, severe sleep apnoea requiring CPAP plus BMI 34, where evidence suggests semaglutide would be clinically transformative
• Scotland, Wales, and Northern Ireland patients: contact your devolved health authority (NHS Scotland, NHS Wales, NI HSC) or speak to your GP about devolved appraisal timelines — some agents may be available sooner or later than in England
• If you choose private access while waiting for NHS: keep your GP informed; some ICBs will accept patients onto the Tier 3 pathway even while on private GLP-1 therapy, allowing transition to NHS when a slot opens
• Use the NHS England "find a service" tool or contact your GP practice manager to identify your closest Tier 3 weight management service and its current waiting time

References

1. NICE Technology Appraisal TA875: Semaglutide for Managing Overweight and Obesity (2023)
2. NICE Technology Appraisal TA1026: Tirzepatide for Managing Overweight and Obesity (2024)
3. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) (2021) — PubMed
4. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) (2022) — PubMed
5. Tirzepatide vs Semaglutide for Obesity (SURMOUNT-5) (2025) — PubMed
6. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial (2023) — PubMed
7. Survodutide for Overweight or Obesity (Phase 2) (2024) — PubMed
8. NHS Digital: Health Survey for England — Adult Obesity Data 2023 (2023)
9. NHS England: Implementation Guidance for Wegovy Specialist Weight Management Services (2023)